Skip to main content

TMEM16A inhibitors as a treatment option for polycystic kidney disease (PKD)

Ref-Nr: TA-B79076


  • TMEM16A inhibitors represent a causative treatment for polycystic kidney disease
  • Significant suppression of renal cysts
  • Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs


Polycystic Kidney Disease (PKD) comprises a group of inherited disorders that lead to multiple fluid-filled renal cysts. The most common form, autosomal dominant PKD (ADPKD), affects 1 in 1000 people, and accounts for 10% of end-stage renal disease, which often necessitates long term treatment, dialysis and/or kidney transplantation.

Bilder & Videos


The Ca2+-regulated chloride ion channel TMEM16A is central to ADPKD. Inhibition of TMEM16A by inhibitors such as the FDA-approved and well-tolerated drugs niclosamide and benzbromarone largely suppress cyst development, as demonstrated in preclinical studies in-vivo. A large number of patients would be likely to benefit from this novel therapeutic concept for the treatment of ADPKD. It could strongly reduce the costs for public health care and lower the patient’s burden caused by invasive medical treatments.


  • TMEM16A inhibitors include FDA approved and well-tolerated drugs such as niclosamide and benzbromarone
  • TMEM16A inhibitors represent a causative treatment for ADPKD
  • Significant suppression of renal cysts

Bayerische Patentallianz GmbH

089 5480177-0
Destouchesstr. 68
80796 München



Angebot Anbieter-Website

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen